Celcuity (NASDAQ:CELC) Receives Buy Rating from Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Celcuity (NASDAQ:CELC) in a research note issued to investors on Friday,Benzinga reports. They currently have a $157.00 price objective on the stock.

A number of other brokerages have also commented on CELC. Wolfe Research reaffirmed an “outperform” rating and issued a $110.00 target price on shares of Celcuity in a research report on Thursday, March 12th. Stifel Nicolaus set a $150.00 price objective on Celcuity in a report on Monday, May 4th. Wall Street Zen lowered Celcuity from a “hold” rating to a “sell” rating in a report on Saturday, April 25th. Citizens Jmp boosted their price objective on Celcuity from $150.00 to $160.00 and gave the stock a “market outperform” rating in a report on Monday, May 4th. Finally, Craig Hallum reissued a “buy” rating and set a $189.00 price objective on shares of Celcuity in a report on Monday, May 4th. Ten analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Celcuity presently has a consensus rating of “Moderate Buy” and a consensus price target of $140.20.

Celcuity Stock Performance

Shares of Celcuity stock opened at $137.68 on Friday. Celcuity has a one year low of $10.26 and a one year high of $151.02. The firm has a market capitalization of $6.66 billion, a price-to-earnings ratio of -35.30 and a beta of 0.09. The business has a 50-day simple moving average of $118.86 and a 200 day simple moving average of $106.73. The company has a debt-to-equity ratio of 3.20, a current ratio of 10.55 and a quick ratio of 10.55.

Celcuity (NASDAQ:CELC) last issued its earnings results on Thursday, May 14th. The company reported ($0.97) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.10. On average, research analysts anticipate that Celcuity will post -3.87 earnings per share for the current fiscal year.

Insider Activity at Celcuity

In related news, Director David Dalvey sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $140.68, for a total value of $3,517,000.00. Following the transaction, the director owned 65,000 shares in the company, valued at approximately $9,144,200. This represents a 27.78% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard E. Buller sold 9,000 shares of the company’s stock in a transaction that occurred on Monday, May 4th. The shares were sold at an average price of $140.46, for a total value of $1,264,140.00. Following the completion of the transaction, the director owned 6,760 shares in the company, valued at approximately $949,509.60. The trade was a 57.11% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 37,000 shares of company stock valued at $5,111,950. 13.33% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Celcuity

Several institutional investors have recently bought and sold shares of the company. NEA Management Company LLC lifted its stake in Celcuity by 64.9% in the fourth quarter. NEA Management Company LLC now owns 3,535,561 shares of the company’s stock valued at $352,637,000 after purchasing an additional 1,391,300 shares during the last quarter. Avoro Capital Advisors LLC purchased a new stake in shares of Celcuity during the fourth quarter worth $310,302,000. Soleus Capital Management L.P. lifted its position in shares of Celcuity by 17.0% during the second quarter. Soleus Capital Management L.P. now owns 3,011,818 shares of the company’s stock worth $40,208,000 after acquiring an additional 437,696 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Celcuity by 10.7% during the fourth quarter. Vanguard Group Inc. now owns 2,279,433 shares of the company’s stock worth $227,351,000 after acquiring an additional 220,386 shares in the last quarter. Finally, State Street Corp lifted its position in shares of Celcuity by 126.6% during the fourth quarter. State Street Corp now owns 1,637,687 shares of the company’s stock worth $163,343,000 after acquiring an additional 914,887 shares in the last quarter. Hedge funds and other institutional investors own 63.33% of the company’s stock.

Celcuity News Roundup

Here are the key news stories impacting Celcuity this week:

• Positive Sentiment: Celcuity announced amendments to its Phase 3 VIKTORIA-2 trial for gedatolisib, expanding the study to include endocrine-sensitive patients with HR-positive, HER2-negative advanced or metastatic breast cancer. The broader trial population could increase the drug’s commercial opportunity if results remain positive. Article Title
• Positive Sentiment: Needham & Company reiterated its Buy rating on Celcuity and raised its price target to $157, signaling continued analyst confidence in the company’s pipeline and upside potential. Article Title
• Positive Sentiment: Celcuity reported first-quarter 2026 earnings of ($0.97) per share, beating consensus estimates of ($1.07). While the company is still unprofitable, the smaller-than-expected loss likely supported investor sentiment. Article Title
• Neutral Sentiment: Celcuity also provided its first-quarter financial results and a corporate update, but the main market focus appears to be on the trial expansion and analyst upgrades rather than the broader financial details. Article Title
• Neutral Sentiment: An earnings call transcript was published for the quarter, which may help investors assess management’s commentary on trial progress, cash needs, and commercialization plans. Article Title

Celcuity Company Profile

Celcuity, Inc is a clinical-stage biotechnology company specializing in precision oncology diagnostics. The company develops and commercializes predictive biomarker assays designed to identify which patients are most likely to benefit from targeted cancer therapies. By integrating functional profiling of tumor cells with molecular analyses, Celcuity seeks to optimize treatment selection and improve outcomes for patients with solid tumors.

Celcuity’s proprietary platform evaluates tumor cell sensitivity to various therapeutic agents using ex vivo assays that measure DNA damage response and other critical pathways.